KRAS and colorectal cancer: BCAM is highly expressed in KRAS-mutant hepatic metastases from colorectal cancer, and inhibition of BCAM/LAMA5 interferes with the adhesion of colorectal cells to vascular endothelial cells, thereby reducing metastatic growth [76].